Esperion Therapeutics Inc (ESPR) 100.53 $ESPR Open

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Esperion Therapeutics Inc (ESPR) 100.53 $ESPR

Open Minded about Closed Offerings
M2 - Tue Apr 21, 8:44AM CDT
Considering that not long ago shareholders would run away the moment that a company announced a secondary offering, it's great to see that the greater investing public is often embracing this key expansionary tool. The standard operating procedure was to employ a static valuation model, based on the dilution compared to the company's current earnings. However, many investors are now also factoring in the company's reasonable future earnings potential into the equity valuation model.
ESPR: 100.53 (-2.60), CACC: 211.50 (+5.39), FISI: 24.02 (+0.49), BXMT: 31.24 (+0.04), VLTC: 15.14 (-1.04)

Critical Alerts For BlackBerry, Hasbro, Esperion Therapeutics, Chesapeake Energy and OmniVision Released By InvestorsObserver
PR Newswire - Tue Apr 21, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BBRY, HAS, ESPR, CHK and OVTI.
HAS: 71.73 (-1.82), ESPR: 100.53 (-2.60), CHK: 14.41 (-0.16), BBRY: 9.92 (-0.11), OVTI: 26.82 (+0.26)

3 Biotech Stocks That Could Be Developing Billion Dollar Drugs
Todd Campbell, The Motley Fool - Motley Fool - Sun Apr 19, 10:07AM CDT
Billion dollar blockbuster status is the Holy Grail pursued by every drugmaker, but developing blockbuster drugs isn't easy. According to the Tufts Center for the Study of Drug Development, it costs $1.4 billion to develop and commercialize a new...
BIIB: 423.57 (+1.46), ESPR: 100.53 (-2.60), GILD: 104.18 (-1.02), ACHN: 10.01 (-0.13), RCPT: 166.76 (-3.37)

3 Top Healthcare Stocks Surging Higher This Year
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 18, 11:03AM CDT
Aging baby boomers and an increasingly insured population are driving healthcare utilization higher, and that has made stocks in this industry some of the market's best performers over the past three years. A number of healthcare stocks are soaring...
ESPR: 100.53 (-2.60), AZN: 73.35 (+0.65), HZNP: 30.96 (+0.10), TEVA: 63.01 (-1.15), EGRX: 60.53 (+1.22), HPTX: 45.96 (-0.18)

The 3 Best Stocks for Investing in Cholesterol Drugs
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 18, 10:04AM CDT
Statins' cholesterol-lowering ability and a growing global need for cholesterol-busting treatment have turned statins into some of the most widely-prescribed drugs in the world. But until recently, investors hoping to profit from the billions of...
ESPR: 100.53 (-2.60), AMGN: 169.10 (+0.64), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41)

Big Pharmas' Dirty Little Secret About Cholesterol Lowering Drugs
Mark Chapman - at Seeking Alpha - Wed Apr 15, 10:19AM CDT

ESPR: 100.53 (-2.60), ALNY: 118.00 (-2.70), MDCO: 27.84 (+0.25), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), AMGN: 169.10 (+0.64), LLY: 72.30 (+0.09), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41)

Esperion Therapeutics to Present at 14th Annual Needham Healthcare Conference
Marketwired - Tue Apr 07, 3:30PM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced that president and chief executive officer, Tim M. Mayleben, will present at the 14th Annual Needham Healthcare Conference in New York City on Tuesday, April 14, 2015 at 1:40 p.m. Eastern Time.
ESPR: 100.53 (-2.60)

Healthcare ratings round up
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 12:23PM CDT

OXGN: 1.49 (-0.02), TRVN: 6.91 (-0.53), ESPR: 100.53 (-2.60), OVAS: 29.85 (-0.24), UHS: 121.07 (+0.12), NLNK: 53.12 (-0.07), RTRX: 24.45 (+0.09), SYK: 96.45 (+1.74)

Here's How Esperion Therapeutics, Inc. Could Get to $140
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 01, 4:27PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Esperion Therapeutics , a clinical-stage...
ESPR: 100.53 (-2.60)

Esperion Up As UBS Touts Cholesterol Drug
at Investor's Business Daily - Wed Apr 01, 2:44PM CDT
Shares of development-stage pharmaceutical firm Esperion Therapeutics (ESPR) jumped 11% Wednesday after UBS initiated coverage of Esperion stock with a buy rating, praising its cholesterol drug candidate. Analyst Andrew Peters wrote that ETC-1002, a...
ESPR: 100.53 (-2.60), MRK: 57.69 (+0.03), AMGN: 169.10 (+0.64), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41)

The Top-Performing Biotech Stock During a Sizzling First Quarter
at The Street - Wed Apr 01, 8:30AM CDT
That was one crazy first quarter for the biotech sector. Here's where biotech stocks stand on April Fool's Day.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), ESPR: 100.53 (-2.60), FMI: 48.71 (-0.96), ANTH: 4.79 (+0.10), XBI: 232.63 (-0.32), IBB: 363.84 (-0.66), TRIL: 20.67 (-2.53)

Healthcare Merger Monday: These 3 Stocks Could Be Healthcare's Next Buyout Targets
Brian Orelli, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Mon Mar 30, 12:43PM CDT
The investment bankers were busy this weekend with four healthcare industry acquisitions announced today. Teva Pharmaceuticals  is buying Auspex Pharmaceuticals for $3.5 billion, Horizon Pharma picked up Hyperion Therapeutics for $1.1 billion,...
ESRX: 86.12 (+0.02), CTRX: 59.46 (-0.11), ESPR: 100.53 (-2.60), ACAD: 38.55 (-0.20), BMRN: 121.08 (-0.16), ICEL: 16.47 (-0.02), UNH: 117.81 (-1.47), HZNP: 30.96 (+0.10), TEVA: 63.01 (-1.15), ASPX: 100.79 (+0.09), ABBV: 64.52 (+0.91), HPTX: 45.96 (-0.18)

3 Little-Known Biotechs Working On Potential Blockbusters
Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 28, 12:08PM CDT
Biotech stocks are prone to jaw-dropping pops and drops, caused by even the hint of positive or negative news surrounding drugs in their pipelines. That makes biotech one of the riskiest industries for investors. However, for those willing to take on...
ESPR: 100.53 (-2.60), PFE: 34.93 (+0.04), OPHT: 52.35 (+1.09), PRTA: 36.96 (+0.36), REGN: 472.63 (+9.41), NVS: 103.45 (-0.62)

First Week of May 15th Options Trading For Esperion Therapeutics (ESPR)
DividendChannel.com - Fri Mar 27, 9:53AM CDT
Investors in Esperion Therapeutics Inc saw new options begin trading this week, for the May 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ESPR options chain for the new May 15th contracts and...
ESPR: 100.53 (-2.60)

3 Biotech Stocks That Dropped Yesterday -- Is 1 a Buy?
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 26, 7:31AM CDT
The biotech stock bubble got a bit deflated this week as the biotech industry ETF tumbled more than 4% on Wednesday. The drop-off in share prices was widespread across the industry, but some stocks were punished more than others. Among those that...
ZIOP: 10.88 (+0.03), ESPR: 100.53 (-2.60), NVAX: 8.51 (+0.09), PFE: 34.93 (+0.04), XON: 44.53 (+0.36)

Why Esperion Therapeutics, Inc. Shares Burst Today.
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 25, 12:16PM CDT
Although we don't believe in   timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Esperion Therapeutics  ...
ESPR: 100.53 (-2.60)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 11:45AM CDT

TANH: 11.82 (+0.40), CCSC: 5.36 (-0.04), STMP: 67.03 (-1.07), HGSH: 3.10 (-0.06), FSNN: 4.38 (+0.12), ATRA: 63.79 (+7.64), KRFT: 88.25 (-0.22), LPTN: 2.26 (unch), IIJI: 8.62 (-0.04), KFX: 11.02 (-0.01), ESPR: 100.53 (-2.60), FCSC: 4.01 (+0.01), ORMP: 7.25 (-0.10), AFMD: 7.94 (+0.11), SEED: 1.66 (+0.05), CALA: 12.93 (-1.06), LIME: 2.85 (-0.12), VBLT: 4.37 (-0.08), APOL: 17.64 (+0.11), REPH: 10.71 (-0.78)

Weakness Seen in Esperion Therapeutics (ESPR): Stock Tumbles 8.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 25, 7:39AM CDT
Make sure to keep an eye on Esperion Therapeutics going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.
ESPR: 100.53 (-2.60)

Esperion closes equity offering
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 3:58PM CDT

ESPR: 100.53 (-2.60)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 160

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 193

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
Mudrick Urges Doncasters to Test a Strategic Sale Now

Updated Category News Views 0

Castings are rarely glamorous until nobody can get them, and Mudrick Capital is betting that ugly little industrial reality could make Doncasters worth far more in a takeover than the market currently credits. The event-driven investor, which says it owns roughly 4.3% of DPC Holdings Limited, has asked the board to quietly evaluate strategic alternatives, including a sale...

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 125

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 102

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 67

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 48

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 55

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 131

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
Roof Leaks Demand Diagnosis Before the Repair Bill

Updated Category News Views 95

A brown ring on a ceiling is often the last witness, not the crime scene. That is the useful, unglamorous point in Jonathan Floyd's HelloNation discussion of roof leaks: water has plenty of ways to move after it slips past a roof's defenses. Homeowners understandably stare at the stain and assume the answer sits directly overhead. Sometimes it does. Plenty of times, it...

Continue Reading

Top 5 Most Recently Viewed Articles

BioMarin's Strong 2024 Performance Fuels 2025 Expectations

Updated Category News Views 392

BioMarin's Empowering Growth Journey Into 2025 BioMarin Pharmaceutical Inc. has marked a significant achievement with its record performance in 2024, setting a strong foundation for the upcoming year. The company demonstrated robust operational execution and is gearing up for a year of potential double-digit revenue growth as it advances its corporate strategy focusing on...

Continue Reading
Berkshire Hills Bancorp Declares Cash Dividend for Shareholders

Updated Category News Views 104

Berkshire Hills Bancorp Announces Quarterly Dividend Berkshire Hills Bancorp, Inc. (NYSE: BHLB) has recently declared a quarterly cash dividend of $0.18 per common share for its shareholders. This decision by the Board of Directors aims to reward shareholders who are on record by a specified date. Details of the Dividend Announcement The approved cash dividend will be...

Continue Reading
Maiden United Transforms Adele's Skyfall into Heavy Metal Epic

Updated Category News Views 167

Maiden United Transforms Iconic Adele Song into Heavy Metal What if Iron Maiden had recorded the legendary James Bond theme song? Maiden United, a notable tribute band dedicated to Iron Maiden, has taken that intriguing concept and turned it into reality. The band has just unveiled their latest EP entitled Agent 666, which features an electrifying heavy metal cover of...

Continue Reading
Cherokee Federal Boosts Growth with MSI, LLC Investment

Updated Category News Views 213

Cherokee Federal Expands Presence Through Strategic Investment Cherokee Federal, a division of Cherokee Nation Businesses (CNB), has recently announced a significant move in the federal contracting realm. They have acquired a majority stake in Management Science and Innovation, LLC, also known as MSI. This strategic investment marks another milestone under their...

Continue Reading
Metallurgical Coal Market Expected Growth Amid Steel Demand Spike

Updated Category News Views 125

Growth of the Metallurgical Coal Market The global metallurgical coal market is poised for significant growth, estimated at USD 95.27 billion from 2024 to 2028. This growth is largely driven by the increasing demand for steel, which is essential for numerous infrastructure projects around the world. As smart city developments surge, the necessity for high-quality steel...

Continue Reading